You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Ultrafast Physical Random Number Generation Using Hybrid Boolean Networks

    SBC: Eno River Technologies Co.            Topic: A14AT002

    Eno River Technologies and Duke University propose to develop Hybrid Boolean Network (HBN) technology for ultrafast physical random number generation. HBNs are circuits composed partly of unclocked logic elements that exhibit chaotic dynamics and clocked elements that provide readout and synchronization to the system bus. It is hypothesized that the chaotic elements amplify electronic noise in t ...

    STTR Phase I 2014 Department of DefenseArmy
  2. Superconducting Parametric Amplifier

    SBC: HYPRES, INC.            Topic: A14AT010

    HYPRES, in collaboration with MIT Lincoln Laboratory and ISQC, proposes to transition superconducting parametric amplifier technology into a robust line of products. In Phase I, we will develop three varieties of superconducting low-noise amplifiers (LNAs) in compact cryogenic microwave packages. These are two types of standing wave devices, lumped-element Josephson parametric amplifier (LJPA) and ...

    STTR Phase I 2014 Department of DefenseArmy
  3. Low Power Monolayer MoS2 Transistors for RF Applications

    SBC: KYMA TECHNOLOGIES, INC.            Topic: A14AT008

    Utilizing a novel solid/gas source CVD reactor designed for the growth of large area (substrates up to 4"in diameter) MoS2 single layer (SL) and multiple layer (ML) films, and leveraging already demonstrated capabilities in the growth and fabrication of 2D-FETs based on graphene and WSe2, we are proposing the growth, fabrication and testing of MoS2-based RF FETs. Utilizing a novel and optimized s ...

    STTR Phase I 2014 Department of DefenseArmy
  4. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Picture Me Fit: Engaging Youth in Community-Based Prevention

    SBC: Prevention Strategies, LLC            Topic: 600

    DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government